Galanin (Human) (Acetate)
(Synonyms: GAL (human), Galanin (1-30)) 目录号 : GC48326
A neuropeptide and GAL receptor agonist
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Human galanin is a 30-amino acid neuropeptide and galanin (GAL) receptor agonist.1,2,3,4 It inhibits forskolin-induced cAMP production in HEK293E cells expressing recombinant human GAL1 receptors (EC50 = 0.031 nM) and stimulates inositol phosphate accumulation in CHO cells expressing recombinant human GAL2 receptors (EC50 = 12.3 nM).1,2 Human galanin induces contractions in isolated rat longitudinal fundus strips with an EC50 value of 13.8 nM.3 Intrathecal administration of human galanin (3, 10, and 30 nmol/animal) reduces paw licking and flinching in the second, but not first, phase of the formalin test in rats.4
1.Fitzgerald, L.W., Patterson, J.P., Conklin, D.S., et al.Pharmacological and biochemical characterization of a recombinant human galanin GALR1 receptor: Agonist character of chimeric galanin peptidesJ. Pharmacol. Exp. Ther.287(2)448-456(1998) 2.Borowsky, B., Walker, M.W., Huang, L.Y., et al.Cloning and characterization of the human galanin GALR2 receptorPeptides19(10)1771-1781(1998) 3.Schmidt, W.E., Kratzin, H., Eckart, K., et al.Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptideProc. Natl. Acad. Sci. USA88(24)11435-11439(1991) 4.Hua, X.-Y., Hayes, C.S., Hofer, A., et al.Galanin acts at GalR1 receptors in spinal antinociception: Synergy with morphine and AP-5J. Pharmacol. Exp. Ther.308(2)574-582(2004)
| Cas No. | SDF | ||
| 别名 | GAL (human), Galanin (1-30) | ||
| Canonical SMILES | O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@H](C(NCC(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@H](C(N[C@H](C(NCC(N4CCC[C@H]4C(N[C@@H](CC5=CNC=N5)C(N[C@H](C(N[C@@H](C(C)C)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN[H])C(N[C@@H](CC(N)=O)C(NCC(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CC(C)C)=O)CC(C)C)=O)=O)=O)C)=O)=O)=O)CC(C)C)=O)=O)CN[H].CC(O)=O | ||
| 分子式 | C139H210N42O43•XC2H4O2 | 分子量 | 3157.4 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3167 mL | 1.5836 mL | 3.1672 mL |
| 5 mM | 0.0633 mL | 0.3167 mL | 0.6334 mL |
| 10 mM | 0.0317 mL | 0.1584 mL | 0.3167 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Regulatory peptides and general neuroendocrine markers in human nasal mucosa, soft palate and larynx
Acta Otolaryngol 1991;111(2):373-8.PMID:1712532DOI:10.3109/00016489109137404.
Various peptide immunoreactivities in the respiratory system have been reported, indicating complex physiological mechanisms. There is only little information on the upper respiratory system of man. The present study was carried out to demonstrate regulatory peptides in the nasal mucosa, larynx (vocal cords and ventricular folds) and soft palate of man using highly efficient immunocytochemical methods. In addition, some peptide immunoreactivities were measured by use of radioimmunoassay (RIA). Using indirect immunofluorescence and immunogold-silver staining (IGSS) with silver Acetate autometallography, a series of peptides could be detected, including vasoactive intestinal polypeptide (VIP), peptide histidine methionine (PHM), galanin, calcitonin gene-related peptide (CGRP), substance P, neuropeptide tyrosine (NPY), C-flanking peptide of NPY (CPON) and somatostatin. In addition, antibodies to protein gene-product (PGP) 9.5, neuron-specific enolase (NSE), S-100, PHE-5 and neurofilament proteins gave positive reactions in tissue sections. Using RIA, CGRP, substance P, and neurokinin A were measured. Our results demonstrate a complex network of regulatory peptide-containing nerve fibers and the possible existence of endocrine cells regulating various functions of the upper respiratory system, which need to be further investigated.